Inclusion Criteria:  Ultrasonographic and/or MRI signs of medial plica pathology; VAS pain 4-8 at time of inclusion; Failure, defined as the persistence of symptomatology, after at least one course of conservative treatment of at least 6 weeks (rest and drug treatment, physiotherapy); Ability and consent of patients to actively participate in clinical follow-up;  Exclusion Criteria:  BMI > 35; Patients with: rheumatic diseases, diabetes, infectious processes, epilepsy, severe stage osteoporosis Patients undergoing intra-tendon infiltration of other substance within the previous 6 months; Patients undergoing surgery on the affected knee within the previous 12 months; Patients undergoing femoro- patellar joint stabilization surgery to the affected knee; Trauma to the affected knee within the past 6 months; Episodes of patellar dislocation and subluxation to the affected knee; State of immunodepression; Ongoing systemic inflammatory diseases (stabilized outcomes of these diseases are not considered absolute contraindications). Contraindications to use or hypersensitivity to the active ingredient (Triamcinolone Acetonide) or to the excipients (sodium chloride, benzyl alcohol, sodium carboxymethylcellulose, polysorbate 80 and water for injectable preparations)found within Kenacort as per the product package insert;  12. Contraindications or hypersensitivity to the active ingredient of the local anesthetic (Lidocaine) or their excipients; 13. Pregnancy or lactation status or intention to become pregnant during the period of study participation. In particular, in the case of a suspected pregnancy , this will be excluded by serological testing (hCG).